Invivyd Inc. (IVVD) dropped some science on Tuesday, and the market responded with a shrug. The biotech announced topline results from its Phase 3 LIBERTY study of VYD2311, an investigational COVID-19 monoclonal antibody candidate, and the data looked solid on both safety and immune response. Yet the stock slid anyway.
The study showed VYD2311 met its primary and key secondary safety endpoints while actually enhancing antibody titers when given alongside an mRNA vaccine. That last part is the interesting bit, because combining an antibody with a vaccine is not always a friendly handshake. Sometimes the two get in each other's way.
Safety And Tolerability Outcomes
The double-blind trial enrolled 210 healthy adults aged 18 to 49 and split them into three arms: VYD2311 alone, the Pfizer Inc. (PFE)/BioNTech SE (BNTX) Comirnaty mRNA vaccine alone, or both treatments together.
Participants who got VYD2311 by itself reported a lower incidence of short-term treatment-emergent adverse events over six days, at 56.5%, compared to 91.4% in the mRNA vaccine group.
Over the full 56 days, VYD2311 kept its favorable tolerability profile with a 60.9% adverse event rate versus 91.4% for the vaccine alone.
Short-term systemic adverse events occurred in 44.1% of participants receiving VYD2311 and 50.0% receiving the combination therapy, both statistically significant reductions compared to 68.1% for the mRNA vaccine alone.
Investigators observed no adverse events exceeding Grade 2 and recorded zero instances of hypersensitivity or anaphylaxis across all treatment groups. That is the kind of clean safety sheet you want when you are asking regulators for a speedy review.
Antibody Titers And Regulatory Strategy
The trial also checked for potential immunologic interference by measuring vaccine-induced neutralizing antiviral titers.
Combining VYD2311 with the mRNA vaccine increased neutralizing titers by approximately 2.5 times compared to the vaccine alone over 56 days.
When researchers removed VYD2311 from combination samples, neutralizing titers remained identical to the standalone vaccine arm, confirming an absence of immunologic interference. In plain English: the antibody did not blunt the vaccine, and the vaccine did not blunt the antibody. They played nicely.
Pharmacokinetic results met company expectations and target profiles under evaluation in the companion DECLARATION trial.
These comparative analyses suggest concomitant administration may improve vaccine safety while expanding neutralizing antiviral coverage.
Following a September Type C meeting and ongoing discussions with U.S. Food and Drug Administration leadership, the company intends to submit a Biologics License Application under the Accelerated Approval Program.
Invivyd will base the application on LIBERTY and DECLARATION data, while continuing post-approval clinical event collection in a randomized confirmatory cohort to evaluate efficacy.
IVVD Price Action: Invivyd shares were down 11.59% at $0.91 at the time of publication on Tuesday, according to market data.
